No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

No­var­tis spin­out resTOR­bio is grap­pling with the col­lapse of its lead clin­i­cal pro­gram this morn­ing — an an­ti-ag­ing R&D fail­ure that will bad­ly dam­age their rep in the field.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER